Jpmorgan Chase & CO Tempest Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	BUY	$0.23 - $9.77 $23 - $1,016	104 Added 1733.33%	110 $0
Q3 2023 Nov 14, 2023	BUY	$0.3 - $1.39 $1 - $8	6 New	6 $0
Q1 2023 May 11, 2023	BUY	$1.14 - $2.91 $356 - $910	313 New	313 $0
Q2 2022 Aug 11, 2022	SELL	$2.08 - $4.15 $274 - $547	-132 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$2.27 - $5.45 $299 - $719	132 New	132 $0

2.46M

44.9K

109K

Ticker TPST
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 10,418,900
Market Cap $9.59M
Description
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxiso...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.